Haemonetics (NYSE:HAE) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen downgraded shares of Haemonetics (NYSE:HAE) from a buy rating to a hold rating in a research report released on Sunday morning.

Several other research analysts have also recently weighed in on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Haemonetics in a report on Monday, December 8th. Citigroup decreased their target price on Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Raymond James Financial reissued an “outperform” rating and set a $90.00 price target on shares of Haemonetics in a report on Friday, November 14th. BTIG Research reaffirmed a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a report on Friday, November 21st. Finally, Needham & Company LLC lifted their target price on Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.90.

Haemonetics Stock Down 1.2%

HAE opened at $83.46 on Friday. The stock’s fifty day simple moving average is $65.38 and its 200 day simple moving average is $64.40. Haemonetics has a 1-year low of $47.31 and a 1-year high of $87.32. The stock has a market cap of $3.91 billion, a PE ratio of 24.40, a price-to-earnings-growth ratio of 1.58 and a beta of 0.29. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating the consensus estimate of $1.12 by $0.15. The firm had revenue of $327.32 million for the quarter, compared to the consensus estimate of $311.61 million. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The company’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.12 earnings per share. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, research analysts expect that Haemonetics will post 4.55 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HAE. AQR Capital Management LLC lifted its position in Haemonetics by 372.8% during the third quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock worth $102,814,000 after purchasing an additional 1,678,630 shares during the period. River Road Asset Management LLC raised its position in shares of Haemonetics by 18.7% in the 2nd quarter. River Road Asset Management LLC now owns 1,655,676 shares of the medical instruments supplier’s stock valued at $122,586,000 after buying an additional 260,624 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Haemonetics by 1.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,244,624 shares of the medical instruments supplier’s stock worth $92,873,000 after acquiring an additional 23,257 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Haemonetics by 2.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock worth $53,587,000 after acquiring an additional 26,763 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in Haemonetics by 2.3% in the first quarter. Royal Bank of Canada now owns 1,075,604 shares of the medical instruments supplier’s stock valued at $68,355,000 after acquiring an additional 24,650 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.